OTCMKTS:HPPI - HedgePath Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.0410 -0.03 (-42.25 %)
(As of 01/23/2019 07:09 AM ET)
Previous Close$0.07
Today's Range$0.0410 - $0.07
52-Week Range$0.0402 - $0.3750
Volume159,439 shs
Average Volume7,704 shs
Market Capitalization$15.17 million
P/E RatioN/A
Dividend YieldN/A
HedgePath Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for patients with cancers in the United States. It primarily focuses on the development of therapies for skin, lung, and prostate cancers. The company's Hedgehog signaling pathway is a primary regulator of cellular processes in vertebrates, including stem cell maintenance, cell differentiation, tissue polarity, and cell proliferation. It is conducting an open-label Phase II (b) clinical trial for studying the effect of SUBA-Itraconazole oral capsules in patients with basal cell carcinoma nevus syndrome. SUBA-Itraconazole is a patented and proprietary itraconazole formulation that enhances the absorption of itraconazole to enhance the bioavailability of orally administered drugs that are poorly soluble. The company was founded in 1992 and is headquartered in Tampa, Florida.

Receive HPPI News and Ratings via Email

Sign-up to receive the latest news and ratings for HPPI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Commercial physical research
Current SymbolOTCMKTS:HPPI



Sales & Book Value

Annual SalesN/A


Net Income$-5,100,000.00


Market Cap$15.17 million
OptionableNot Optionable

HedgePath Pharmaceuticals (OTCMKTS:HPPI) Frequently Asked Questions

What is HedgePath Pharmaceuticals' stock symbol?

HedgePath Pharmaceuticals trades on the OTCMKTS under the ticker symbol "HPPI."

When is HedgePath Pharmaceuticals' next earnings date?

HedgePath Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, February 15th 2019. View Earnings Estimates for HedgePath Pharmaceuticals.

Has HedgePath Pharmaceuticals been receiving favorable news coverage?

Media headlines about HPPI stock have been trending positive recently, according to InfoTrie Sentiment. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. HedgePath Pharmaceuticals earned a media sentiment score of 2.4 on InfoTrie's scale. They also gave news stories about the company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the company's share price in the next few days.

Who are some of HedgePath Pharmaceuticals' key competitors?

Who are HedgePath Pharmaceuticals' key executives?

HedgePath Pharmaceuticals' management team includes the folowing people:
  • Mr. Nicholas J. Virca, Pres & CEO (Age 73)
  • Mr. Garrison J. Hasara CPA, CPA, CFO, Treasurer, Chief Compliance Officer & Sec. (Age 50)

How do I buy shares of HedgePath Pharmaceuticals?

Shares of HPPI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is HedgePath Pharmaceuticals' stock price today?

One share of HPPI stock can currently be purchased for approximately $0.0410.

How big of a company is HedgePath Pharmaceuticals?

HedgePath Pharmaceuticals has a market capitalization of $15.17 million. HedgePath Pharmaceuticals employs 3 workers across the globe.

What is HedgePath Pharmaceuticals' official website?

The official website for HedgePath Pharmaceuticals is http://www.hedgepathpharma.com.

How can I contact HedgePath Pharmaceuticals?

HedgePath Pharmaceuticals' mailing address is 324 S. Hyde Park Avenue Ste. 350, Tampa FL, 33606. The company can be reached via phone at 813-864-2559 or via email at [email protected]

MarketBeat Community Rating for HedgePath Pharmaceuticals (OTCMKTS HPPI)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  130 (Vote Outperform)
Underperform Votes:  163 (Vote Underperform)
Total Votes:  293
MarketBeat's community ratings are surveys of what our community members think about HedgePath Pharmaceuticals and other stocks. Vote "Outperform" if you believe HPPI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HPPI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/23/2019 by MarketBeat.com Staff

Featured Article: Quiet Period

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel